Protein Design Labs (PDLI): Stock strong

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Protein Design Labs (PDLI): Stock strong

An SI Board Since February 1997

Posts	SubjectMarks	Bans	Symbol
407	58	0	PDLI

Emcee: Stanley Cowen	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
382	Tuck- Were there any hints previously as to the Nuvion issues and ultimate cess	Biotech Jim	-	8/29/2007
381	<i>then blew out of the stock as fast as they could.<i> They're	tom pope	-	8/29/2007
380	Notable calls gathers analyst color on this move (and feels it's shortable h	tuck	-	8/29/2007
379	Not an encouraging message to give anybody contemplating the job. OTOH Merrill d	tom pope	-	8/29/2007
378	They did the same thing with lgnd, pushed for asset sales, got their special div	rkrw	-	8/29/2007
377	I think it's the BOD being prodded by Third Point, trying to get its way bef	tuck	-	8/29/2007
376	I think it's the BOD being prodded by Third Point, trying to get its way bef	tuck	-	8/29/2007
375	I would have thought that a decision such as this would have been deferred unti	tom pope	-	8/28/2007
374	Indeed, there was some hope for Nuvion in UC; the stock is now off 13% after hou	tuck	-	8/28/2007
373	>>PDL BioPharma Announces Significant Strategic and Portfolio Changes to F	tuck	-	8/28/2007
372	End of drama: PDL BioPharma Mark McDade Resigning; Internal Investigation Finds	idos	-	8/20/2007
371	2Q results were solid, both on product sales and royalty revenues: PDL BioPharm	idos	-	8/2/2007
370	The drama continues . . . >>After Meeting with PDL's Non-Manage	tuck	-	7/16/2007
369	Third Point Asks PDL BioPharma To Close Investigation Into CEO McDade`s Suspecte	Doc Bones	-	6/3/2007
368	8:01AM PDL BioPharma says Nuvion antibody led to sustained response and remissio	idos	-	5/22/2007
367	Merrill. That first sentence is pretty wishy washy. Assume business as usual, b	tom pope	-	5/21/2007
366	From Briefing. A gentleman who does not mince words. It was worth 50 cents AH:	tom pope	-	5/7/2007
365	Merrill: 1Q misses on lower royalties, but raises ’07 guidance PDL reported 1Q0	tom pope	-	5/3/2007
364	Market yawned: LOS ANGELES, May 2 (Reuters) - PDL Biopharma Inc. <PDLI.O>	tom pope	-	5/2/2007
363	April 11 (Reuters) - PDL BioPharma Inc.'s (PDLI.O: Quote, Profile , Research	keokalani'nui	-	4/11/2007
362	The stock is up more than 6% on this PDL shareholder calls for CEO resignation	idos	-	4/11/2007
361	Merrill's comment on that: Daclizumab phase II study meets endpoint in MS P	tom pope	-	3/13/2007
360	Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing M	nigel bates	-	3/12/2007
359	PDLI is likely to receive royalties of 3% or slightly greater on Actemra sales w	idos	-	1/25/2007
358	Merrill PDL’s ’07 royalties off to good start on Genentech’s sales PDL receives	tom pope	-	1/11/2007

Go to reply# or date (mm/dd/yy):